Magic Touch®: preliminary clinical evidence with a novel sirolimus drug coated balloon.

Drug-coated balloons (DCB) have been developed in recent years to overcome some of the drug-eluting stents limitations. There is an established indication for the use of DCB in the treatment of in-stent restenosis and they are also variably used in various setting, in particular small coronary vessels and bifurcations. Until 2016, all DCBs available in Europe eluted paclitaxel, a highly lipophilic drug with narrow therapeutic window. In April 2016 a new sirolimus-coated balloon (Magic Touch®, Envision Scientific PVT, Bhatpore, India) obtained the CE Mark. This device shares a new-generation delivery system and is able to release in a few seconds an effective dosage of sirolimus.